Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Chemotherapy in R/R AML
NCT02299518Phase 1Completed
- Start
- May 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in acute myeloid leukemia (AML) (2 cohorts). Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2015; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02299518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299518.